Mutation landscape of acquired cross-resistance to glycopeptide and β-lactam antibiotics in Enterococcus faecium.

Antimicrob Agents Chemother

INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Equipe 12, Paris, France Sorbonne Universités, UPMC Université Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France Université Paris Descartes, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, F

Published: September 2015


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Bypass of the d,d-transpeptidase activity of penicillin-binding proteins by an l,d-transpeptidase (Ldtfm) results in resistance to ampicillin and glycopeptides in Enterococcus faecium M9, a mutant obtained by nine consecutive selection steps. Resistance requires activation of a cryptic locus for production of the essential tetrapeptide-containing substrate of Ldtfm and impaired activity of protein phosphatase StpA. Here, whole-genome sequencing revealed a high mutation rate for the entire selection procedure (79 mutations in 900 generations). Acquisition of a mutation in the mismatch repair gene mutL had little impact on the frequency of rifampin-resistant mutants although the mutation spectrum of M9 was typical of impaired MutL with high transversion to transition (40/11) and substitution to deletion (51/28) ratios. M9 did not mainly accumulate neutral mutations since base substitutions occurred more frequently in coding sequences than expected (χ(2) = 5.0; P < 0.05) and silent mutations were underrepresented (χ(2) = 5.72; P < 0.02). None of the mutations directly affected recognition of the tetrapeptide substrate of Ldtfm by peptidoglycan synthesis enzymes. Instead, mutations appear to remodel regulatory circuits involving two-component regulatory systems and sugar metabolism. The high number of mutations required for activation of the l,d-transpeptidase pathway may strongly limit emergence of cross-resistance to ampicillin and glycopeptides by this mechanism.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538475PMC
http://dx.doi.org/10.1128/AAC.00634-15DOI Listing

Publication Analysis

Top Keywords

enterococcus faecium
8
ampicillin glycopeptides
8
substrate ldtfm
8
mutations
6
mutation
4
mutation landscape
4
landscape acquired
4
acquired cross-resistance
4
cross-resistance glycopeptide
4
glycopeptide β-lactam
4

Similar Publications

Listeria monocytogenes poses a serious food safety risk due to its ability to survive and grow on produce during cold storage. This study evaluates Enterococcus faecium NRRL B-2354 as a non-pathogenic surrogate for L. monocytogenes during up to 24 weeks of simulated lab storage and 36 weeks of commercial storage, including refrigerated air (RA), controlled atmosphere (CA), CA with 1-methylcyclopropene (1-MCP), with or without gaseous ozone treatment.

View Article and Find Full Text PDF

Objectives: Vancomycin-resistant enterococcal bloodstream infections (VRE-BSIs) carry high mortality in patients with malignancy. While neutropenia is a known risk factor for mortality in patients with malignancy and BSI, its impact on the effectiveness of daptomycin and linezolid in VRE-BSI is not well defined.

Methods: We conducted a multicenter cohort study of hospitalized patients aged ≥18 years with malignancy and VRE-BSI between 2010 and 2021.

View Article and Find Full Text PDF

Novel Enterococcus phage BUCT630: Isolation and genomic insights targeting drug-resistant Enterococcus faecium in vitro and in vivo.

Microb Pathog

September 2025

College of Life Sciences and Technology, Beijing University of Chemical Technology, Beijing, 100029, China; Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, 100029, China. Electronic address:

The antibiotic-resistant Enterococcus faecium (E. faecium) is a significant health issue requiring alternative therapies. Phages could be an alternative to antibiotics and have promising activity in both in vitro and in vivo experiments.

View Article and Find Full Text PDF

In Vitro synergy of Farnesyltransferase inhibitors in combination with colistin against ESKAPE bacteria.

PLoS One

September 2025

Faculty of Health, Institute of Pharmacology and Toxicology, Centre for Biomedical Education and Research (ZBAF), School of Medicine, Witten/Herdecke University, Witten, Germany.

The emergence of antibiotic resistance continues to pose a significant global challenge. Drug repurposing, wherein existing therapeutics are evaluated for new applications, offers a promising strategy to address this issue. Farnesyltransferase inhibitors (FTIs), initially developed for cancer therapy, have demonstrated antimicrobial activity against several gram-positive bacteria.

View Article and Find Full Text PDF

Management of MDR/XDR severe infections in the critically ill.

Curr Opin Crit Care

October 2025

ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore, Singapore.

Purpose Of Review: This review aims to summarize current recommendations for the management of serious infections, such as bloodstream infections (BSIs) and ventilator-associated pneumonia, caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens, focusing on evidence from randomized controlled trials (RCTs) and emerging treatment options.

Recent Findings: Vancomycin, linezolid, and daptomycin represent the main therapeutic options for the management of methicillin-resistant Staphylococcus aureus infections; among newer agents, ceftobiprole has recently gained approval for BSI treatment. For vancomycin-resistant Enterococcus faecium BSIs, linezolid and daptomycin remain commonly employed despite the lack of comparative RCTs guiding treatment decisions.

View Article and Find Full Text PDF